The latest price target for Evolus (NASDAQ:EOLS) was reported by HC Wainwright & Co. on November 7, 2024. The analyst firm set a price target for $27.00 expecting EOLS to rise to within 12 months (a possible 147.93% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Evolus (NASDAQ:EOLS) was provided by HC Wainwright & Co., and Evolus reiterated their buy rating.

The last upgrade for Evolus Inc happened on January 29, 2024 when Barclays raised their price target to $16. Barclays previously had an equal-weight for Evolus Inc.

There is no last downgrade for Evolus.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evolus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evolus was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest Evolus (EOLS) rating was a reiterated with a price target of $27.00 to $27.00. The current price Evolus (EOLS) is trading at is $10.89, which is out of the analyst’s predicted range.